QT PRODACT: Evaluation of the potential of compounds to cause QT interval prolongation by action potential assays using guinea-pig papillary muscles

Journal of Pharmacological Sciences

Volumn 99, Issue 5, 2005, Pages 449-457

  Kii, Yoshihide ^a,b   Hayashi, Seiji ^a,c   Tabo, Mitsuyasu ^a,d   Shimosato, Takashi ^a,e   Fukuda, Hitoshi ^a,f   Itoh, Tetsuji ^a,g   Amano, Hideto ^a,h   Saito, Mamoru ^a,i   Morimoto, Hajime ^a,j   Yamada, Kiyoshi ^a,k   Kanda, Atsuhiro ^a,l   Ishitsuka, Toshimasa ^a,m   Yamazaki, Takanobu ^a,n   Kiuchi, Yoichi ^a,o   Taniguchi, Shinya ^a,p   Mori, Tatsuya ^a,q   Shimizu, Shigekazu ^a,r   Tsurubuchi, Yuji ^a,s   Yasuda, Shun Ichi ^a,t   Kitani, Shin Ichi ^a,u   Shimada, Chiaki ^a,v   Kobayashi, Kazuo ^a,w   Komeno, Masaharu ^a,x   Kasai, Chieko ^a,y   Hombo, Toshiyasu ^a,y   Yamamoto, Keiji ^a,z   more..

^a Japan Pharmaceutical Manufacturers Association JPMA/QT PRODACT   (Japan)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^c NIPPON SHINYAKU CO LTD   (Japan)

^d CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^e NISSEI BILIS Co Ltd   (Japan)

^f TOYAMA CHEMICAL CO LTD   (Japan)

^g SHIONOGI AND CO LTD   (Japan)

^h MITSUBISHI CHEMICAL CORPORATION   (Japan)

ⁱ EISAI CO LTD   (Japan)

^j OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^k TORAY INDUSTRIES INC   (Japan)

^l TAIHO PHARMACEUTICAL CO LTD   (Japan)

^m MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

ⁿ KYORIN PHARMACEUTICAL CO LTD   (Japan)

^o TAISHO PHARMACEUTICAL CO LTD   (Japan)

^p AJINOMOTO CO INC   (Japan)

^q KYOWA HAKKO KOGYO CO LTD   (Japan)

^r Fuji Biomedix Co Ltd   (Japan)

^s Drug Safety Testing Center Co Ltd   (Japan)

^t Nihon Bioresearch Inc   (Japan)

^u N   (Japan)

^v Fuso Pharmaceutical Industries Ltd   (Japan)

^w DAIICHI SANKYO CO   (Japan)

^x ONO PHARMACEUTICAL CO   (Japan)

^y ASTELLAS PHARMA INC   (Japan)

^z TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

more..

Author keywords

Action potential duration (APD) between 30 and 60 repolarization (APD30 60); APD30 90; APD60 90; Human ether a go go related gene (hERG) current; QT PRODACT

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; ACETYLSALICYLIC ACID; AMOXICILLIN; ASTEMIZOLE; BEPRIDIL; CALCIUM CHANNEL; CAPTOPRIL; CIPROFLOXACIN; CISAPRIDE; DIPHENHYDRAMINE; DISOPYRAMIDE; FLECAINIDE; HALOPERIDOL; LIDOCAINE; NIFEDIPINE; PIMOZIDE; POTASSIUM CHANNEL; PROPRANOLOL; PROTEIN INHIBITOR; QUINIDINE; TERFENADINE; THIORIDAZINE; VERAPAMIL; CALCIUM CHANNEL BLOCKING AGENT; DELAYED RECTIFIER POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ARTICLE; CALCIUM CURRENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; GUINEA PIG; HEART PAPILLARY MUSCLE; HEART REPOLARIZATION; MALE; NONHUMAN; POTASSIUM CURRENT; QT PROLONGATION; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; FACTUAL DATABASE; IN VITRO STUDY; LONG QT SYNDROME; PHYSIOLOGY;

ACTION POTENTIALS; ANIMALS; CALCIUM CHANNEL BLOCKERS; DATABASES, FACTUAL; DELAYED RECTIFIER POTASSIUM CHANNELS; ETHER-A-GO-GO POTASSIUM CHANNELS; GUINEA PIGS; LONG QT SYNDROME; MALE; PAPILLARY MUSCLES; POTASSIUM CHANNEL BLOCKERS;

EID: 33645089223     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.QT-C8     Document Type: Article

References (30)

1. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58:32-45. (The full, electronic version of this article is available on; http://www.elsevier.com/homepage/sab/cardio/doc/Redfern_full.pdf).
2. Curtis LH, Ostbye T, Sendersky V, Hutchison S, Allen LaPointe NM, Al-Khatib SM, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med. 2003;114:135-141.
3. ICH Harmonised Tripartite Guideline, The Non-clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals S7B. Recommended for adoption at step 4 of the ICH process on 12 May 2005 by the ICH Steering Committee. ICH; http://www.ich.org/.
4. Hayashi S, Kii Y, Tabo M, Fukuda H, Itoh T, Shimosato T, et al. QT PRODACT: A multi-site study of in vitro action potential assays on 21 compounds in isolated guinea-pig papillary muscles. J Pharmacol Sci. 2005;99:423-437.
5. Hondeghem LM, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation. 2001;103:2004-2013.
6. Hondeghem LM, Lu HR, van Rossem K, De Clerck F. Detection of proarrhythmia in the female rabbit heart: blinded validation. Cardiovasc Electrophysiol. 2003;14:287-294.
7. Martin RL, McDermott JS, Salmen HJ, Palmatier J, Cox BF, Gintant GA. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J Cardiovasc Pharmacol. 2004;43:369-379.
8. Snyders DJ, Chaudhary A. High affinity open channel block by dofetilide of HERG expressed in a human cell line. Mol Pharmacol. 1996;49:949-955.
9. Lu HR, Vlaminckx E, Van Ammel K, De Clerck F. Drug-induced long QT in isolated rabbit Purkinje fibers: importance of action potential duration, triangulation and early after-depolarizations. Eur J Pharmacol. 2002;452:183-192.
10. Matsuoka S, Sarai N, Kuratomi S, Ono K, Noma A. Role of individual ionic current systems in ventricular cells hypothesized by a model study. Jpn J Physiol. 2003;53:105-123.
11. Yatani A, Brown AM, Schwartz A. Bepridil block of cardiac calcium and sodium channels. J Pharmacol Exp Ther. 1986;237:9-17.
12. 2+ current in guinea pig ventricular myocytes by cisapride. J Biomed Sci. 2004;11:303-314.
13. Hiraoka M, Kuga K, Kawano S, Sunami A, Fan Z. New observations on the mechanisms of antiarrhythmic actions of disopyramide on cardiac membranes. Am J Cardiol. 1989;64:15J-19J.
14. Ca in single frog cardiac cells by quinidine, flecainide, ethmozin, and ethacizin. Am J Physiol. 1989;256:C549-C559.
15. Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Saf. 2000;23:215-228.
16. 2+ channel blocker in heart. Mol Pharmacol. 1990;37:752-757.
17. 2+ current in rat ventricular cardiomyocytes. Pharmacology. 2002;65:187-192.
18. + channels in guinea pig ventricular myocytes. J Cardiovasc Pharmacol. 1995;26:761-769.
19. 2+ channel current in rat ventricular myocytes by terfenadine. Circ Res. 1997;81:202-210.
20. Wegener JW, Nawrath H. Extracellular site of action of phenylalkylamines on L-type calcium current in rat ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol. 1995;352:322-330.
21. Omata T, Kasai C, Hashimoto M, Hombo T, Yamamoto K. QT PRODACT: Comparison of non-clinical studies for druginduced delay in ventricular repolarization and their role in safety evaluation in humans. J Pharmacol Sci. 2005;99:531-541.
22. Khalifa M, Drolet B, Daleau P, Lefez C, Gilbert M, Plante S, et al. Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine. J Pharmacol Exp Ther. 1999; 288:858-865.
23. 1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res. 1995;76:110-119.
24. Drolet B, Khalifa M, Daleau P, Hamelin BA, Turgeon J. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation. 1998;97:204-210.
25. + current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol. 1990;96:195-215.
26. + current of guinea-pig ventricular myocytes. J Mol Cell Cardiol. 1996;28:893-903.
27. + channel HERG. Mol Pharmacol. 2001;59:122-126.
28. + channel by the neuroleptic pimozide. Eur J Pharmacol. 2000;392:137-140.
29. Kang J, Chen XL, Wang L, Rampe D. Interactions of the anti-malarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG. J Pharmacol Exp Ther. 2001;299:290-296.
30. Dupuis DS, Klaerke DA, Olesen SP. Effect of β-adrenoceptor blockers on human ether-a-go-go-related gene (HERG) potassium channels. Basic Clin Pharmacol Toxicol. 2005;96:123-130.